Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 3/20 | 0.46 |
| ▸ | TREH | O43280 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | PYGB | P11216 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.37 |
| ▸ | CD69 | Q07108 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18806954 | 1.00 | OGA (0.46) | OGATREHALDH1A1THRBMAPK1 | |
| SCHEMBL13389865 | 1.00 | OGA (0.46) | OGATREHALDH1A1THRBMAPK1 | |
| SCHEMBL12085189 | 1.00 | OGA (0.46) | OGATREHALDH1A1THRBMAPK1 | |
| SCHEMBL16869797 | 1.00 | OGA (0.46) | OGATREHALDH1A1THRBMAPK1 | |
| SCHEMBL23603516 | 1.00 | OGA (0.46) | OGATREHALDH1A1THRBMAPK1 | |
| SCHEMBL18857573 | 1.00 | OGA (0.46) | OGATREHALDH1A1THRBMAPK1 | |
| SCHEMBL23705039 | 1.00 | OGA (0.46) | OGATREHALDH1A1THRBMAPK1 | |
| SCHEMBL16221822 | 1.00 | OGA (0.46) | OGATREHALDH1A1THRBMAPK1 | |
| SCHEMBL10803673 | 1.00 | OGA (0.46) | OGATREHALDH1A1THRBMAPK1 | |
| SCHEMBL12178004 | 1.00 | OGA (0.46) | OGATREHALDH1A1THRBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120064652-A | Application of differentially expressed serum protein glycoform as biological detection marker for helicobacter pylori negative gastric cancer diagnosis | 西北大学 | 2025-05-30 | — | — | CN | claimed |
| EP-4543897-A1 | ELECTROCHEMICAL BIOSENSING ELECTRODE BASED ON SIALYLATED GLYCAN FOR THE DETECTION OF NEURAMINIDASES OR SIALYLTRANSFERASES | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2025-04-30 | — | — | EP | claimed |
| WO-2023248217-A1 | ELECTROCHEMICAL BIOSENSING ELECTRODE BASED ON SIALYLATED GLYCAN FOR THE DETECTION OF NEURAMINIDASES OR SIALYLTRANSFERASES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-12-28 | — | — | WO | claimed |
| CN-111690041-B | Polypeptide with anti-tumor activity and preparation method thereof | 上海大学 | 2022-06-07 | — | — | CN | claimed |
| CN-122005775-A | Group B streptococcus oligosaccharide protein conjugate and preparation method and application thereof | 山东大学 | 2026-05-12 | — | — | CN | disclosed |
| US-20250222088-A1 | MULTIVALENT VACCINE COMPOSITIONS AND USES THEREOF | Janssen Pharmaceuticals, Inc. | 2025-07-10 | — | — | US | disclosed |
| CN-114555817-B | Rhamnose polysaccharide | 敦提大学 | 2025-06-10 | — | — | CN | disclosed |
| CN-120064652-A | Application of differentially expressed serum protein glycoform as biological detection marker for helicobacter pylori negative gastric cancer diagnosis | 西北大学 | 2025-05-30 | — | — | CN | disclosed |
| CN-113950524-B | Methods of producing bioconjugates of E.coli O-antigen polysaccharides, compositions thereof, and methods of use thereof | 杨森制药公司 | 2025-05-02 | — | — | CN | disclosed |
| EP-4543897-A1 | ELECTROCHEMICAL BIOSENSING ELECTRODE BASED ON SIALYLATED GLYCAN FOR THE DETECTION OF NEURAMINIDASES OR SIALYLTRANSFERASES | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2025-04-30 | — | — | EP | disclosed |
| US-20250114386-A1 | COMBINATION OF A GLYCOSYLATION INHIBITOR WITH ONE CAR CELL THERAPY FOR TREATING CANCER | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2025-04-10 | — | — | US | disclosed |
| EP-4508429-A1 | MEANS AND METHODS FOR HIGH-THROUGHPUT GLYCOPROFILING OF PROTEINS | Glycanostics s.r.o. (SK) | 2025-02-19 | — | — | EP | disclosed |
| WO-2022051575-A2 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTION | HASSAN AMEER E (US) | 2022-03-10 | — | — | WO | disclosed |
| CN-114126619-A | Compounds for the synthesis of peptidomimetics | 范因斯坦医学研究院 | 2022-03-01 | — | — | CN | disclosed |
| CN-105454235-B | 2 acetylaminos 1,5, application of the 2 deoxidation D glucitols of dehydration in water resistant rice bacterial leaf spot pathogenic bacteria active medicine is prepared | 华中农业大学 | 2017-08-08 | — | — | CN | disclosed |
| CN-105454235-A | Application of 2-acetamido-1,5,-dehydrated-2-deoxy-D-glucitol to preparation of anti-rice-leaf-blight-bacterial-activity medicine | UNIV HUAZHONG AGRICULTURAL | 2016-04-06 | — | — | CN | disclosed |
| US-4868157-A | IMMUNOLOGY | MERCK & CO., INC. (US) | 1989-09-19 | — | — | US | disclosed |
| EP-0041896-B1 | IMMUNOLOGICALLY ACTIVE DIPEPTIDYL 2-AMINO-1,2-DIDEOXY-D-GLUCOSE DERIVATIVES AND METHODS OF PREPARATION | MERCK & CO. INC. (US) | 1983-12-28 | — | — | EP | disclosed |
| US-4315913-A | BACTERICIDES, VIRICIDES, PARASITICIDES VACCINE | MERCK & CO. INC. (US) | 1982-02-16 | — | — | US | disclosed |
| EP-0041896-A1 | Immunologically active dipeptidyl 2-amino-1,2-dideoxy-D-glucose derivatives and methods of preparation | MERCK & CO. INC. (US) | 1981-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250222088-A1 | MULTIVALENT VACCINE COMPOSITIONS AND USES THEREOF | MLEC, ENGASE, CD63 | OGA 113/4885TREH 1970/4885ALDH1A1 4845/4885 |
| US-20250114386-A1 | COMBINATION OF A GLYCOSYLATION INHIBITOR WITH ONE CAR CELL THERAPY FOR TREATING CANCER | ST6GAL1, ENGASE, MAN2A1 | OGA 40/4885TREH 432/4885ALDH1A1 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.